Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.

[1]  S. Kaplan,et al.  Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia , 2006, Expert opinion on drug metabolism & toxicology.

[2]  J. Mulhall,et al.  Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. , 2006, The journal of sexual medicine.

[3]  U. Jonas,et al.  In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. , 2006, Urology.

[4]  A. Billis.  Immunohistochemical Distribution of cAMP-and cGMP-Phosphodiesterase ( PDE ) Isoenzymes in the Human Prostate , 2006 .

[5]  B. Stuckey,et al.  Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. , 2005, The journal of sexual medicine.

[6]  G. Bartsch,et al.  1348: Sildenafil Citrat Causes a 3 Fold Increase in Periurethral Prostatic Blood Flow , 2004 .

[7]  M. Kiniwa,et al.  1338: Desirable Therapeutic Approach on Benign Prostate Hyperplasia; Proposal from Anti-Androgen Therapy on Novel Stromal Hyperplasia Model , 2004 .

[8]  C. Roehrborn,et al.  Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. , 2004, Urology.

[9]  S. Toler,et al.  Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. , 2003, The Journal of urology.

[10]  E. Kulinskaya,et al.  Sildenafil influences lower urinary tract symptoms , 2002, BJU international.

[11]  R. Young,et al.  Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor. , 2002, Bioorganic & medicinal chemistry letters.

[12]  U. Jonas,et al.  Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. , 2001, The Journal of urology.

[13]  J. Dall'ava-Santucci,et al.  [In vitro study of the modulation of human ureteral tonus by nitric oxide and zaprinast, a phosphodiesterase inhibitor]. , 2000, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[14]  P. Boyle,et al.  Double‐blind, placebo‐controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH , 1998, The Prostate.

[15]  P. Alken,et al.  LU 302 872 and its racemate (LU 224 332) show balanced endothelin-A/B receptor affinity, high oral activity, and inhibit human prostate tissue contractions. , 1998, Journal of cardiovascular pharmacology.

[16]  T. Chirikos,et al.  Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. , 1996, The Journal of urology.

[17]  J. Johansson,et al.  Can finasteride reverse the progress of benign prostatic hyperplasia? a two-year placebo-controlled study , 1995 .

[18]  J. Hieble,et al.  The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. , 1996, Pharmacological research.

[19]  K. Kurth,et al.  Placebo Controlled Double-blind Study to Test the Efficacy of the Aromatase Inhibitor Atamestane in Patients with Benign Prostatic Hyperplasia not Requiring Operation , 1995 .

[20]  M. Barry,et al.  Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). , 1994, Urology.

[21]  M. Barry,et al.  Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). , 1994, Urology.

[22]  R. Challiss,et al.  Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. , 1991, TIPS - Trends in Pharmacological Sciences.

[23]  M. Barry,et al.  Epidemiology and natural history of benign prostatic hyperplasia. , 1990, The Urologic clinics of North America.

[24]  L. Brunton,et al.  Functional compartments in cyclic nucleotide action. , 1982, Journal of cyclic nucleotide research.